PepGen Inc.: insider trading
88 trades by 15 directors, officers and 10% owners since 2022, from their SEC Form 4 and 5 filings.
Bought, 12 months
$43.1 M
1 purchase by 1 insider
Sold, 12 months
$59 K
7 sales by 4 insiders
Bought, 3 months
$43.1 M
1 purchase
Sold, 3 months
$0
0 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (15)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Ra Capital Management, L.P.Director, 10% owner | — | $43.1 M | — | |
| Kasra KasraianChief Technical Officer | 50,074 | — | $2 K | |
| James G. McArthurPresident and CEO, Director | 296,326 | — | $33 K | |
| Noel DonnellyChief Financial Officer | 111,603 | — | $13 K | |
| Paul StreckEVP, Head of R&D | 76,226 | — | $12 K | |
| Joseph VittiglioChief Business & Legal Officer | 65,717 | — | — | |
| Oxford Science Enterprises plcFormer 10% Owner | 4.96 M | — | — | |
| RA Capital Healthcare Fund LPDirector, 10% owner | — | — | — | |
| Mary Beth DeLenaGeneral Counsel | 14,968 | — | — | |
| Michelle L. MellionChief Medical Officer | 0 | — | — | |
| Niels SvenstrupSVP, Chem. Mfg & Controls | 0 | — | — | |
| Peter KolchinskyDirector, 10% owner | — | — | — | |
| Jaya GoyalEVP, Res. & Preclin. Dev. | 0 | — | — | |
| Deerfield Private Design Fund V, L.P.10% owner | — | — | — | |
| Laurie KeatingDirector | 4,166 | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ra Capital Management, L.P.Director, 10% owner | Buyindirect | +8.63 M | $5.000 | $43.1 M | 27.18 M | Form 4 |
| filed | Kasra KasraianChief Technical Officer | Sell10b5-1 plan | -1,233 | $1.410 | $2 K | 50,074 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -5,144 | $6.230 | $32 K | 296,457 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Sell10b5-1 plan | -1,832 | $6.230 | $11 K | 76,273 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Sell10b5-1 plan | -2,032 | $6.230 | $13 K | 111,655 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -131 | $6.330 | $829 | 296,326 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Sell10b5-1 plan | -52 | $6.330 | $329 | 111,603 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Sell10b5-1 plan | -47 | $6.290 | $296 | 76,226 | Form 4 |
| filed | Kasra KasraianChief Technical Officer | Grant or award | +34,557 | — | — | 51,307 | Form 4 |
| filed | Joseph VittiglioChief Business & Legal Officer | Grant or award | +30,717 | — | — | 65,717 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Grant or award | +50,300 | — | — | 78,105 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Grant or award | +187,688 | — | — | 301,601 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Grant or award | +76,793 | — | — | 113,687 | Form 4 |
| filed | Joseph VittiglioChief Business & Legal Officer | Grant or award | +35,000 | — | — | 35,000 | Form 4 |
| filed | Oxford Science Enterprises plcFormer 10% Owner | Buy | +200,000 | $3.200 | $640 K | 4.96 M | Form 4 |
| filed | RA Capital Healthcare Fund LPDirector, 10% owner | Buyindirect | +9.38 M | $3.200 | $30.0 M | 18.55 M | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Buy | +8,375 | $1.240 | $10 K | 27,805 | Form 4 |
| filed | Kasra KasraianChief Technical Officer | Grant or award | +16,750 | — | — | 16,750 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Buy | +10,000 | $1.360 | $14 K | 113,913 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Buy | +41,500 | $1.150 | $48 K | 103,913 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Grant or award | +60,719 | — | — | 62,413 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Grant or award | +19,430 | — | — | 19,430 | Form 4 |
| filed | Mary Beth DeLenaGeneral Counsel | Grant or award | +13,400 | — | — | 14,968 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Grant or award | +23,283 | — | — | 24,956 | Form 4 |
| filed | Mary Beth DeLenaGeneral Counsel | Sell10b5-1 plan | -1,432 | $1.680 | $2 K | 1,568 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Sell10b5-1 plan | -1,527 | $1.680 | $3 K | 1,673 | Form 4 |
| filed | Mary Beth DeLenaGeneral Counsel | Grant or award | +3,000 | — | — | 3,000 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Grant or award | +3,200 | — | — | 3,200 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +7,571 | $10.21 | $77 K | 7,571 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -7,571 | $18.06 | $137 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +201 | $10.21 | $2 K | 201 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -201 | $18.01 | $4 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +12,625 | $10.21 | $129 K | 12,625 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -12,625 | $18.20 | $230 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +5,901 | $10.21 | $60 K | 5,901 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -5,901 | $18.00 | $106 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +3,288 | $10.21 | $34 K | 3,288 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -3,288 | $18.04 | $59 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +37 | $10.21 | $378 | 37 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -37 | $18.07 | $669 | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +875 | $10.21 | $9 K | 875 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -875 | $18.01 | $16 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +9,260 | $10.21 | $95 K | 9,260 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -9,260 | $18.19 | $168 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +1,086 | $10.21 | $11 K | 1,086 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -1,086 | $18.06 | $20 K | 0 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Option exercise10b5-1 plan | +500 | $10.21 | $5 K | 500 | Form 4 |
| filed | Michelle L. MellionChief Medical Officer | Sell10b5-1 plan | -500 | $18.04 | $9 K | 0 | Form 4 |
| filed | Michelle L. MellionSVP, Clinical Development | Option exercise10b5-1 plan | +1,411 | $10.21 | $14 K | 1,411 | Form 4 |
| filed | Michelle L. MellionSVP, Clinical Development | Sell10b5-1 plan | -1,411 | $18.00 | $25 K | 0 | Form 4 |
| filed | Michelle L. MellionSVP, Clinical Development | Option exercise10b5-1 plan | +7,245 | $10.21 | $74 K | 7,245 | Form 4 |
| filed | Michelle L. MellionSVP, Clinical Development | Sell10b5-1 plan | -7,245 | $18.09 | $131 K | 0 | Form 4 |
| filed | Niels SvenstrupSVP, Chem. Mfg & Controls | Sell10b5-1 plan | -10,000 | $13.41 | $134 K | 0 | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Buyindirect | +2.56 M | $10.64 | $27.2 M | 9.18 M | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Buy | +1,694 | $4.170 | $7 K | 1,694 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Option exercise10b5-1 plan | +2,381 | $2.710 | $6 K | 2,381 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -2,381 | $16.04 | $38 K | 0 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Option exercise10b5-1 plan | +8,419 | $2.710 | $23 K | 8,419 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -8,419 | $16.23 | $137 K | 0 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Option exercise10b5-1 plan | +18,150 | $2.710 | $49 K | 18,150 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -18,150 | $16.18 | $294 K | 0 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Option exercise10b5-1 plan | +500 | $2.710 | $1 K | 500 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -500 | $16.06 | $8 K | 0 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Option exercise10b5-1 plan | +1,800 | $2.710 | $5 K | 1,800 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -1,800 | $16.04 | $29 K | 0 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Option exercise10b5-1 plan | +392 | $10.88 | $4 K | 392 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Sell10b5-1 plan | -392 | $20.00 | $8 K | 0 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Option exercise10b5-1 plan | +644 | $10.88 | $7 K | 644 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Sell10b5-1 plan | -644 | $17.00 | $11 K | 0 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Option exercise10b5-1 plan | +3,679 | $10.88 | $40 K | 3,679 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Sell10b5-1 plan | -3,679 | $17.18 | $63 K | 0 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Option exercise10b5-1 plan | +1,677 | $10.88 | $18 K | 1,677 | Form 4 |
| filed | Jaya GoyalEVP, Res. & Preclin. Dev. | Sell10b5-1 plan | -1,677 | $17.04 | $29 K | 0 | Form 4 |
| filed | Niels SvenstrupSVP, Chem. Mfg & Controls | Option exercise | +10,000 | $2.710 | $27 K | 10,000 | Form 4 |
| filed | Oxford Science Enterprises plc10% owner | Buyamended | +879,970 | $12.00 | $10.6 M | 4.76 M | Form 4/A |
| filed | Peter KolchinskyDirector, 10% owner | Conversionindirect | +3.64 M | — | — | 3.64 M | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Buyindirect | +2.98 M | $12.00 | $35.8 M | 6.62 M | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Conversionindirect | +1.05 M | — | — | 1.05 M | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Buyindirect | +249,749 | $12.00 | $3.0 M | 1.30 M | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Conversionindirect | +207,672 | — | — | 207,672 | Form 4 |
| filed | Deerfield Private Design Fund V, L.P.10% owner | Conversionindirect | +268,480 | — | — | 268,480 | Form 4 |
| filed | Oxford Science Enterprises plc10% owner | Conversion | +1.26 M | — | — | 1.38 M | Form 4 |
| filed | Deerfield Private Design Fund V, L.P.10% owner | Conversionindirect | +268,480 | — | — | 268,480 | Form 4 |
| filed | Oxford Science Enterprises plc10% owner | Conversion | +945,859 | — | — | 2.33 M | Form 4 |
| filed | Deerfield Private Design Fund V, L.P.10% owner | Buyindirect | +208,333 | $12.00 | $2.5 M | 476,813 | Form 4 |
| filed | Oxford Science Enterprises plc10% owner | Conversion | +1.55 M | — | — | 3.88 M | Form 4 |
| filed | Deerfield Private Design Fund V, L.P.10% owner | Buyindirect | +208,333 | $12.00 | $2.5 M | 476,813 | Form 4 |
| filed | Laurie KeatingDirector | Buy | +4,166 | $12.00 | $50 K | 4,166 | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice